Vanguard Capital Management
PRME icon

Vanguard Capital Management’s Prime Medicine PRME Stock Holding History

Vanguard Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
4,522,640
+48,478
+1% +$161K ﹤0.01% 2548
2026
Q1 		$15.6M Buy
+4,474,162
New +$17M ﹤0.01% 2483

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's PRME Position: Q2 2026 in Review

Vanguard Capital Management increased its Prime Medicine (PRME) stake by 1.1% in Q2 2026, buying an estimated $161K and bringing the position to 4,522,640 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2548.

Vanguard Capital Management first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard Capital Management held 4,522,640 shares of Prime Medicine worth $16.7M as of Q2 2026.
  • Vanguard Capital Management bought 48,478 Prime Medicine shares in Q2 2026, an estimated $161K.
  • Prime Medicine made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2548 holding.
  • Vanguard Capital Management first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.